Science
Mechanism of Action
Excavatolide B precisely modulates inflammatory cascades by inhibiting the mRNA expression of key proinflammatory mediators, including inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), within macrophages. It demonstrably reduces iNOS protein expression and the infiltration of immune cells, concurrently decreasing vascular permeability. A distinctive mechanism involves the covalent engagement of STING at its membrane-proximal Cys91, thereby inhibiting STING palmitoylation and subsequent signaling. In models of atopic dermatitis, EXCB regulates inflammatory proteins, vascular endothelial growth factor (VEGF), and various cytokines (e.g., IL-1β, IL-6, IL-17A). Furthermore, it aids in restoring critical skin barrier proteins (loricrin, filaggrin, claudin-1) and modulates angiogenesis, contributing to both inflammation reduction and tissue regeneration.
Research
Clinical Evidence
Medium confidenceN/A
Key findings
- 01 Significantly attenuated carrageenan-induced nociceptive behaviors, mechanical allodynia, thermal hyperalgesia, weight bearing deficits, and paw edema. Inhibited iNOS and immune cell infiltration in inflammatory paw tissue.
- 02 Significantly inhibited mRNA expression of proinflammatory mediators (iNOS, COX-2), vascular endothelial growth factor (VEGF), and cytokines (IL-1β, IL-6, IL-17A) in LPS-challenged cells.
- 03 Alleviated skin symptoms of atopic dermatitis, reduced serum levels of IgE, IL-4, IL-13, IL-17, and interferon-γ. Moderated histological hyperplasia, inflammatory cell infiltration, and angiogenesis. Restored skin barrier proteins (loricrin, filaggrin, claudin-1) and reduced angiogenesis-related proteins (VEGF, CD31).
- 04 Reduced wound area, decreased immune cell and mast cell infiltration. Reduced cGAS-STING pathway factors and M1 macrophages while increasing angiogenic factors (VEGF, CD31), M2 macrophages, and collagen I/III deposition. Promoted human dermal fibroblast migration and proliferation.
Transparency
Dusting Analysis
Excavatolide B is primarily a research-stage compound with robust preclinical data, not widely used in consumer products, hence not subject to 'dusting' concerns.
The Formula
Formulation
Stability
Excavatolide B is reported to be stable when isolated from cultured coral. It was dissolved in 100% dimethyl sulfoxide (DMSO) for cell culture experiments. The development of derivatives (e.g., EXCB-61 salt, EXCB-79) to enhance its solubility suggests the native compound may present formulation challenges, particularly in aqueous systems.
Safety
Safety Profile
No specific safety assessments by major regulatory bodies such as CIR, SCCS, or FDA for Excavatolide B have been identified. Studies in animal models have reported 'low toxicity', however, comprehensive human safety data for topical cosmetic application, including sensitization risk, is currently unavailable.
Your Skin
Skin Compatibility
Our Assessment
Verdict
Excavatolide B demonstrates significant preclinical promise in anti-inflammatory and wound healing capacities, warranting further rigorous research into human topical efficacy, solubility optimization, and comprehensive safety for cosmetic applications.
Related
Similar Ingredients
Finding similar ingredients…
References
Sources